First Tracks Biotherapeutics, Inc. (TRAX) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
First Tracks Biotherapeutics, Inc. (TRAX) with a net loss of $163.71M, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. posted — in revenue in fiscal 2024.
It clears 1 of 2 deterministic health checks. Nothing in the filed statements trips our red-flag scan.
Synthesised from First Tracks Biotherapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about First Tracks Biotherapeutics, Inc.? Check it against the filing
Open the full tool →Paste a headline number you saw about TRAX — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
First Tracks Biotherapeutics, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Net income | $-106.15M | $-163.71M |
| Net margin | — | — |
Source: First Tracks Biotherapeutics, Inc. SEC filings (10-K).
First Tracks Biotherapeutics, Inc. financial health: 1 of 2 checks passed
- ✓More cash than total debt (cash 385.4M vs debt 0M)
- ✗Free cash flow positive (latest yr) (-126.2M)
Checks computed deterministically from filed annual statements — no AI judgement.
First Tracks Biotherapeutics, Inc.: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
Explore 2 years of First Tracks Biotherapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track TRAX in your portfolio →
First Tracks Biotherapeutics, Inc. financial history
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
First Tracks Biotherapeutics, Inc. — frequently asked questions
Is First Tracks Biotherapeutics, Inc. profitable?
No — TRAX reported a net loss of $-163.71M in fiscal 2024.
What is First Tracks Biotherapeutics, Inc.'s market cap?
First Tracks Biotherapeutics, Inc. (TRAX) has a market capitalization of about $600.50M, based on the latest data in our nightly-refreshed cache.
When does First Tracks Biotherapeutics, Inc.'s fiscal year end?
TRAX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2024-12-31.
Where does this data come from?
All figures are computed from First Tracks Biotherapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.